{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:15:49Z","timestamp":1790727349555,"version":"4.1.0"},"reference-count":60,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,1,12]],"date-time":"2014-01-12T00:00:00Z","timestamp":1389484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"name":"Japan Health Science Foundation"},{"name":"Japanese Ministry of Health, Labor, and Welfare"},{"DOI":"10.13039\/501100001700","name":"Japanese Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"crossref","award":["24310146"],"award-info":[{"award-number":["24310146"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2014,2]]},"abstract":"Measles virus (MV<\/jats:styled-content>) is one of the candidates for the application of oncolytic virotherapy (OVT<\/jats:styled-content>). Although an advanced clinical study has been reported on a T\u2010cell lymphoma, the potential of MV OVT<\/jats:styled-content> against B\u2010cell lymphomas remains to be clarified. We found that an EBV<\/jats:styled-content>\u2010transformed B lymphoblastoid cell line, a model for diffuse large B\u2010cell lymphoma, and EBV<\/jats:styled-content>\u2010positive Burkitt's lymphoma cells bearing type III<\/jats:styled-content> latency were highly susceptible to the cytolysis induced by an MV<\/jats:styled-content> vaccine strain CAM<\/jats:styled-content>\u201070. As analyzed by EBV<\/jats:styled-content>\u2010positive and \u2010negative counterparts of the same cytogenetic background, type III EBV<\/jats:styled-content> latency, not type I, was shown to augment the susceptibility of B lymphoma cells to MV<\/jats:styled-content>\u2010induced cytolysis. Cell surface levels of CD<\/jats:styled-content>150\/signaling lymphocytic activation molecule, a receptor of MV<\/jats:styled-content>, were upregulated in B lymphoma cell lines with type III EBV<\/jats:styled-content> latency by 3.8\u2010fold, on average. The cytolytic activity of CD<\/jats:styled-content>150\u2010tropic WT MV<\/jats:styled-content> was akin to that of CD<\/jats:styled-content>46\u2010 and CD<\/jats:styled-content>150\u2010tropic CAM<\/jats:styled-content>\u201070, suggesting that CD<\/jats:styled-content>150 is critical for the susceptibility to MV<\/jats:styled-content>\u2010induced cytolysis. Among EBV<\/jats:styled-content>\u2010encoded genes, latent membrane protein 1 was responsible for the CD<\/jats:styled-content>150 upregulation. It was notable that the majority of B lymphoma cell lines of type III EBV<\/jats:styled-content> latency showed higher susceptibility to the non\u2010Edmonston\u2010derived CAM<\/jats:styled-content>\u201070 than to the Edmonston\u2010derived Schwarz strain. This is the first report indicating the potential of non\u2010Edmonston MV<\/jats:styled-content> strain for the application of OVT<\/jats:styled-content>. Furthermore, a cellular regulator of MV<\/jats:styled-content> replication was implicated that functions in a vaccine strain\u2010specific fashion. Altogether, the MV OVT<\/jats:styled-content> should serve as an alternative therapy against EBV<\/jats:styled-content>\u2010positive diffuse large B\u2010cell lymphoma with type III EBV<\/jats:styled-content> latency.<\/jats:p>","DOI":"10.1111\/cas.12324","type":"journal-article","created":{"date-parts":[[2013,11,15]],"date-time":"2013-11-15T17:03:12Z","timestamp":1384534992000},"page":"211-218","source":"Crossref","is-referenced-by-count":17,"title":["Enhanced susceptibility of B<\/scp> lymphoma cells to measles virus by E<\/scp>pstein\u2013B<\/scp>arr virus type III<\/scp> latency that upregulates CD<\/scp>150\/signaling lymphocytic activation molecule"],"prefix":"10.1111","volume":"105","author":[{"given":"Satoshi","family":"Takeda","sequence":"first","affiliation":[{"name":"AIDS Research Center National Institute of Infectious Diseases Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Kanbayashi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Virology Division Osaka Prefectural Institute of Public Health Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Kurata","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Virology Division Osaka Prefectural Institute of Public Health Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Yoshiyama","sequence":"additional","affiliation":[{"name":"Research Center for Infection\u2010associated Cancer Institute for Genetic Medicine Hokkaido University Sapporo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Komano","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Virology Division Osaka Prefectural Institute of Public Health Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2287"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-012-9548-2"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(87)90441-7"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5286.373"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0697-639"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq165"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.3675"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.146"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3089"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)80071-L"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.67.10.6025-6032.1993"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.1995.tb03700.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4558"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920112800958896"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.69.6.3955-3958.1995"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir097"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2762"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2011.75"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(71)90869-5"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(71)91186-X"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(71)92086-1"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5863.421"},{"key":"e_1_2_7_24_1","first-page":"61","article-title":"Spontaneous remission in Burkitt's lymphoma","volume":"44","author":"Ziegler JL","year":"1976","journal-title":"Natl Cancer Inst Monogr"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1978.03630320073024"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90865-3"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)90112-0"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.12.3746"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.7.2002"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0502-527"},{"key":"e_1_2_7_31_1","first-page":"2462","article-title":"Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme","volume":"63","author":"Phuong LK","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0670-3"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210240"},{"key":"e_1_2_7_34_1","first-page":"2655","volume-title":"Fields Virology","author":"Rickinson AB","year":"2007"},{"key":"e_1_2_7_35_1","first-page":"2603","volume-title":"Fields Virology","author":"Kieff E","year":"2007"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/35022579"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.20.10427-10436.2002"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2011.01924.x"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00571929"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.128.5.1011"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/21.5.954"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-71-7-1481"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10498"},{"key":"e_1_2_7_44_1","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.4049\/jimmunol.151.9.4614","article-title":"Characterization of a cell surface glycoprotein IPO\u20103, expressed on activated human B and T lymphocytes","volume":"151","author":"Sidorenko SP","year":"1993","journal-title":"J Immunol"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.4.1989"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxh083"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/17.6.1700"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.6.3072-3077.2002"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2010.14"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.010"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.8.10.1581"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2871"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-561-9_35"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2010.02.006"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2181"},{"key":"e_1_2_7_56_1","first-page":"276","article-title":"Establishment and characterization of an Epstein\u2010Barr virus (EBC)\u2010negative lymphoblastoid B cell line (BJA\u2010B) from an exceptional, EBV\u2010genome\u2010negative African Burkitt's lymphoma","volume":"22","author":"Menezes J","year":"1975","journal-title":"Biomedicine"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.68.9.6069-6073.1994"},{"key":"e_1_2_7_58_1","first-page":"309","article-title":"The use of lymphomatous and lymphoblastoid cell lines in the study of Burkitt's lymphoma","volume":"60","author":"Lenoir GM","year":"1985","journal-title":"IARC Sci Publ"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.1.5.1045-1051.1967"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.1.1.116-117.1975"},{"key":"e_1_2_7_61_1","first-page":"547","article-title":"Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji)","volume":"37","author":"Epstein MA","year":"1966","journal-title":"J Natl Cancer Inst"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcas.12324","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcas.12324","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.12324","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cas.12324","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.12324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T10:33:28Z","timestamp":1694342008000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.12324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,12]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1111\/cas.12324"],"URL":"https:\/\/doi.org\/10.1111\/cas.12324","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,12]]}}}